Section Editor: Aad Tibben, email: email@example.com
Colonoscopy use following mutation detection in Lynch syndrome: exploring a role for cancer screening in adaptation
Article first published online: 19 JAN 2011
Published 2011. This article is a US Government work and is in the public domain in the USA
Volume 79, Issue 4, pages 321–328, April 2011
How to Cite
Hadley, D., Ashida, S., Jenkins, J., Calzone, K., Kirsch, I. and Koehly, L. (2011), Colonoscopy use following mutation detection in Lynch syndrome: exploring a role for cancer screening in adaptation. Clinical Genetics, 79: 321–328. doi: 10.1111/j.1399-0004.2010.01622.x
- Issue published online: 4 MAR 2011
- Article first published online: 19 JAN 2011
- Accepted manuscript online: 28 DEC 2010 01:26AM EST
- Received 22 October 2010, revised and accepted for publication 22 December 2010
- genetic testing;
- health behavior;
- HNPCC/ L ynch syndrome
Hadley DW, Ashida S, Jenkins JF, Calzone KA, Kirsch IR, Koehly LM. Colonoscopy use following mutation detection in Lynch syndrome: exploring a role for cancer screening in adaptation.
Lynch syndrome (LS) is the most common inherited form of colorectal cancer. Mutation carriers can reduce the morbidity and mortality associated with colorectal cancer through colonoscopy. Theoretical models suggest that such health-related behaviors might also bring psychological benefits. This study assessed whether colonoscopy following mutation detection was associated with the levels of depressive symptoms. Data were obtained from a prospective family cohort study offering genetic services for LS. Participants completed questionnaires prior to the provision of services and 6 months post-receipt of mutation results. One hundred thirty-four (134) persons were identified to carry a mutation and completed both the questionnaires. Main outcome measures were depressive symptoms 6 months post-receipt of test results. Mutation carriers who did not complete a colonoscopy within the 6 months following receipt of results were six times (p < 0.01; odds ratio = 6.06) more likely to report depressive symptoms at a level of clinical importance post-receipt of test results compared to those who did undergo colonoscopy. Facilitating the expeditious use of colonoscopy following mutation detection may benefit newly identified mutation carriers by addressing the objective risks for cancer and moderating underlying emotional distress responses to genetic risk information. Furthermore, depressive symptoms may interfere with behavioral compliance in some patients, suggesting referral to mental health specialists.